For the quarter ending 2026-03-31, LCTX had -$4,848K decrease in cash & cash equivalents over the period. -$8,133K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss attributable to lineage | -4,812 | 851 | -29,781 | -34,603 |
| Amortization of intangible assets | - | 0 | 0 | 0 |
| Net income (loss) attributable to noncontrolling interest | 23 | 41 | 29 | 96 |
| Issuance costs for common stock warrant liabilities | 0 | 0 | 0 | 183 |
| Loss on impairment of intangible asset | - | 0 | 0 | 14,840 |
| (gain) loss on marketable equity securities, net | 24 | -7 | 6 | -7 |
| Accretion of income on marketable debt securities | 163 | 34 | 0 | 10 |
| Foreign currency remeasurement and other loss | - | - | - | 1,455 |
| Depreciation and amortization expense | 188 | 186 | 178 | 335 |
| Change in right-of-use assets and liabilities | -8 | -17 | 47 | -88 |
| Stock-based compensation | 1,172 | 1,098 | 1,199 | 2,455 |
| Change in fair value of warrant liability | -2,324 | -1,265 | 26,557 | 10,435 |
| Deferred income tax benefit | - | -5,280 | - | - |
| Foreign currency remeasurement | 24 | 548 | 1,721 | - |
| Loss on disposal of assets | -12 | - | - | - |
| Accounts receivable | -154 | 827 | -130 | -381 |
| Prepaid expenses and other current assets | -434 | 1,031 | 194 | -1,271 |
| Accounts payable and accrued liabilities | -1,711 | 2,459 | 271 | -459 |
| Deferred revenue | -995 | -518 | -1,780 | -3,813 |
| Net cash used in operating activities | -8,078 | -4,878 | -3,616 | -10,425 |
| Proceeds from the sale of marketable equity securities | - | 0 | 0 | 0 |
| Purchases of marketable debt securities | 8,236 | 14,935 | 0 | 0 |
| Maturities of marketable debt securities | 5,965 | 0 | 0 | 2,000 |
| Purchase of equipment | 55 | 399 | 12 | 111 |
| Net cash (used in) provided by investing activities | -2,326 | -15,334 | -12 | 1,889 |
| Proceeds from sale of common shares, net of offering costs-Direct Financing | - | 0 | 0 | 0 |
| Proceeds from employee options exercised | 227 | 763 | 487 | 0 |
| Proceeds from sale of common shares, net of offering costs-At The Market | - | 19,632 | 1,276 | 0 |
| Proceeds from exercise of warrants | 5,388 | 0 | 319 | - |
| Common shares received and retired for employee taxes paid | 40 | 1 | 0 | 15 |
| Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs | 0 | 0 | 0 | 5,232 |
| Payment of financed insurance premium | 0 | 0 | 232 | 452 |
| Payment of finance lease liabilities | 14 | 15 | 16 | 28 |
| Net cash provided by financing activities | 5,561 | 20,379 | 1,834 | 4,737 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -5 | 180 | -4 | 220 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -4,848 | 347 | -1,798 | -3,579 |
| At beginning of the period | 41,324 | 40,977 | -7 | - |
| At end of the period | 36,476 | 41,324 | 40,977 | - |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)